Intellia Therapeutics Inc. [NASDAQ: NTLA] traded at a high on 11/13/20, posting a 11.85 gain after which it closed the day’ session at $33.23. The company report on November 11, 2020 that Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments.
Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients.
Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease (SCD) treatments using its CRISPR/Cas9 genome editing technology. This pilot development program is part of the Gates Foundation’s broader initiative to accelerate the advancement of safe, effective and durable gene-based cures in developing countries within the next seven to 10 years. The funding from the Gates Foundation will advance Intellia’s preclinical validation of in vivo hematopoietic stem cells (HSCs) genome editing using the company’s proprietary non-viral delivery systems and CRISPR/Cas9 technology to potentially cure SCD.
The results of the trading session contributed to over 1371919 shares changing hands. Over the past one week, the price volatility of Intellia Therapeutics Inc. stands at 7.06% while the volatility over the past one month is 7.24%.
The market cap for NTLA stock reached $1.76 billion, with 58.75 million shares outstanding and 49.26 million shares in the current float. Compared to the average trading volume of 906.26K shares, NTLA reached a trading volume of 1371919 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Intellia Therapeutics Inc. [NTLA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NTLA shares is $35.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NTLA stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Intellia Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 27, 2020. The new note on the price target was released on October 14, 2020, representing the official price target for Intellia Therapeutics Inc. stock. Previously, the target price had yet another raise to $33, while Goldman analysts kept a Buy rating on NTLA stock.
The Average True Range (ATR) for Intellia Therapeutics Inc. is set at 2.15, with the Price to Sales ratio for NTLA stock in the period of the last 12 months amounting to 28.17. The Price to Book ratio for the last quarter was 5.92, with the Price to Cash per share for the same quarter was set at 7.72.
How has NTLA stock performed recently?
Intellia Therapeutics Inc. [NTLA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.42. With this latest performance, NTLA shares gained by 37.03% in over the last four-week period, additionally plugging by 77.70% over the last 6 months – not to mention a rise of 145.60% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NTLA stock in for the last two-week period is set at 75.35, with the RSI for the last a single of trading hit 83.58, and the three-weeks RSI is set at 71.35 for Intellia Therapeutics Inc. [NTLA]. The present Moving Average for the last 50 days of trading for this stock 23.67, while it was recorded at 30.16 for the last single week of trading, and 18.75 for the last 200 days.
Intellia Therapeutics Inc. [NTLA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Intellia Therapeutics Inc. [NTLA] shares currently have an operating margin of -246.78. Intellia Therapeutics Inc.’s Net Margin is presently recorded at -230.92.
Return on Total Capital for NTLA is now -37.57, given the latest momentum, and Return on Invested Capital for the company is -35.52. Return on Equity for this stock declined to -36.34, with Return on Assets sitting at -29.21. When it comes to the capital structure of this company, Intellia Therapeutics Inc. [NTLA] has a Total Debt to Total Equity ratio set at 6.81. Additionally, NTLA Total Debt to Total Capital is recorded at 6.37, with Total Debt to Total Assets ending up at 5.50. Long-Term Debt to Equity for the company is recorded at 4.68, with the Long-Term Debt to Total Capital now at 4.38.
Reflecting on the efficiency of the workforce at the company, Intellia Therapeutics Inc. [NTLA] managed to generate an average of -$368,641 per employee. Receivables Turnover for the company is 7.09 with a Total Asset Turnover recorded at a value of 0.13.Intellia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.50 and a Current Ratio set at 7.50.
Earnings analysis for Intellia Therapeutics Inc. [NTLA]
With the latest financial reports released by the company, Intellia Therapeutics Inc. posted -0.57/share EPS, while the average EPS was predicted by analysts to be reported at -0.56/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -1.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NTLA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Intellia Therapeutics Inc. go to 30.00%.
Insider trade positions for Intellia Therapeutics Inc. [NTLA]
There are presently around $1,856 million, or 85.00% of NTLA stock, in the hands of institutional investors. The top three institutional holders of NTLA stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 11,404,752, which is approximately 0.012% of the company’s market cap and around 0.90% of the total institutional ownership; NIKKO ASSET MANAGEMENT AMERICAS, INC., holding 6,062,516 shares of the stock with an approximate value of $201.46 million in NTLA stocks shares; and SUMITOMO MITSUI TRUST HOLDINGS, INC., currently with $201.46 million in NTLA stock with ownership of nearly -2.142% of the company’s market capitalization.
Positions in Intellia Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 91 institutional holders increased their position in Intellia Therapeutics Inc. [NASDAQ:NTLA] by around 7,699,382 shares. Additionally, 57 investors decreased positions by around 2,091,179 shares, while 35 investors held positions by with 46,077,406 shares. The mentioned changes placed institutional holdings at 55,867,967 shares, according to the latest SEC report filing. NTLA stock had 32 new institutional investments in for a total of 3,506,846 shares, while 24 institutional investors sold positions of 725,291 shares during the same period.